EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China

Wei Jiang, Wei Zhong, Jingdi Yu, Yufei Tang, Qunyi Guo

Frontiers in Oncology · 18.06.2026 · 16

DOI: 10.3389/fonc.2026.1687341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 18.06.2026. Verfasst von Wei Jiang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Shangyu People's Hospital of Shaoxing, Shaoxing, China. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pomalidomide, a next-generation immunomodulatory drug (IMiD), and carfilzomib, a novel proteasome inhibitor (PI), have been separately approved in combination regimens for relapsed/refractory multiple myeloma (RRMM). However, real-world data, particularly for Chinese RRMM patients with prior-line treatment, including lenalidomide and bortezomib, remain limited.

Methods

We retrospectively analyzed RRMM patients treated with KPd between October 2022 and December 2024 at two Chinese centers.

Results

This study included 34 patients who received KPd. The median age was 65 years. All patients were bortezomib-exposed, 91.2% were lenalidomide-exposed (and refractory), and 50.0% were daratumumab-exposed. The overall response rate (ORR) was 82.4% and was significantly influenced by high-risk cytogenetics, prior daratumumab exposure, and the receipt of ≥ 3 prior lines of therapy. The median progression-free survival (PFS) was 13 months, with a 2-year PFS rate of 40.3%. Hematologic toxicities were the most common adverse events (AEs) (73.5%), and grade 3/4 AEs occurred in 58.8% of patients.

Conclusions

KPd exhibited substantial effectiveness in this real-world cohort of heavily pretreated Chinese RRMM patients, including those with lenalidomide-refractory disease. However, the high incidence of hematologic toxicities necessitates careful monitoring and management.

Schlagwörter

Stichwörter der Autor:innen

carfilzomibdexamethasonemultiple myelomapomalidomidereal-world

Autor:innen und Institutionen

  • Department of Hematology, Shangyu People's Hospital of Shaoxing, Shaoxing, China.
  • Department of Hematology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China.

Zitieren

APA

Jiang, W., Zhong, W., Yu, J., Tang, Y., & Guo, Q. (2026). Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1687341

Vancouver

Jiang W, Zhong W, Yu J, Tang Y, Guo Q. Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1687341

BibTeX
@article{Jiang2026,
  author = {Jiang, Wei and Zhong, Wei and Yu, Jingdi and Tang, Yufei and Guo, Qunyi},
  title = {Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1687341}
}
Kostenlos starten →